CHARLESTON – As the landmark federal opioid trial entered its fourth week, plaintiffs jumped into McKesson Corporation’s threshold guidelines and due diligence process.
During testimony on May 24, McKesson Corp. Director of Regulatory Affairs Michael Oriente testified that the Controlled Substance Monitoring Program was being developed as he transitioned into the DRA position.
Under CSMP, a threshold system was created for all schedule two through five substances. Oriente said customers only were permitted to receive up to the threshold number and then they would be blocked. McKesson had a three-level review process to determine if the order was suspicious. Faber
McKesson distribution centers are sectioned into four districts and have five DRA positions, according to Oriente.